Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05195918 · ClinicalTrials.gov registry record · Phase 1
Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients
A Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Hal Chapman.
- Active
- Registry status
- Phase 1
- Development phase
- 50
- Enrollment target
- 7
- Study locations
NCT05195918: Active Phase 1 study of Idiopathic Pulmonary Fibrosis, sponsored by Hal Chapman.
NCT05195918 is a Phase 1 study of Idiopathic Pulmonary Fibrosis that is active but no longer recruiting, run by Hal Chapman. The registered enrollment target is 50 participants, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower). The trial reports 7 study locations across 7 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05195918, a Phase 1 study of Idiopathic Pulmonary Fibrosis, is active but no longer recruiting, sponsored by Hal Chapman.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 1
- Development phase
- 50 participants
- Enrollment target
- 7
- Study locations
Study Summary
The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
Primary Outcome
The number of participants with at least 1 treatment-emergent adverse event
Conditions Studied
Interventions
- COMBINATION_PRODUCT EGCG 300 mg + Nintedanib
- COMBINATION_PRODUCT EGCG 300 mg + Pirfenidone
- COMBINATION_PRODUCT Placebo 2 capsules + Nintedanib or Pirfenidone
- COMBINATION_PRODUCT EGCG 600 mg + Nintedanib
- COMBINATION_PRODUCT EGCG 600 mg + Pirfenidone
Study Locations (7)
California
- UCSF Parnassus - San Francisco
Massachusetts
- Massachusetts General Hospital - Boston
Michigan
- University of Michigan - Ann Arbor
New York
- Weill Cornell Medicine - New York
Pennsylvania
- Temple University - Philadelphia
Virginia
- University of Virginia - Charlottesville
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2023-08-24 |
| Est. Completion | 2026-04-21 |
| Phase | Phase 1 |
What the registry record for NCT05195918 still lists
NCT05195918 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 751-participant average among 51 other Idiopathic Pulmonary Fibrosis trials with a reported enrollment target (93% lower).
The record links to 1 condition, with Idiopathic Pulmonary Fibrosis appearing as the primary indexed condition, and to 5 interventions - of which EGCG 300 mg + Nintedanib is the first listed.
NCT05195918 lists 7 locations in 7 states (California, Massachusetts, Michigan).
Frequently Asked Questions
What is clinical trial NCT05195918 about?
NCT05195918 is a clinical study titled "Study of Oral Epigallocatechin-3-gallate (EGCG) in IPF Patients". The primary purpose of this multi-center, double-blind, placebo-controlled, dose-ranging Phase I study is to assess the safety of a purified from green tea, EGCG, in patients with idiopathic pulmonary fibrosis (IPF) as a potential novel treatment for pulmonary fibrosis.
What is the current status of trial NCT05195918?
This trial is currently active not recruiting. It is a Phase 1 study. The enrollment target is 50 participants. The study started on 2023-08-24. Estimated completion is 2026-04-21.
What conditions does trial NCT05195918 study?
This clinical trial studies the following conditions: Idiopathic Pulmonary Fibrosis.
What interventions are being tested in trial NCT05195918?
The interventions under investigation include: EGCG 300 mg + Nintedanib (COMBINATION_PRODUCT), EGCG 300 mg + Pirfenidone (COMBINATION_PRODUCT), Placebo 2 capsules + Nintedanib or Pirfenidone (COMBINATION_PRODUCT), EGCG 600 mg + Nintedanib (COMBINATION_PRODUCT), EGCG 600 mg + Pirfenidone (COMBINATION_PRODUCT).
Who is sponsoring clinical trial NCT05195918?
This trial is sponsored by Hal Chapman, which has 3 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05195918 being conducted?
This trial has 7 study locations across California, Massachusetts, Michigan, New York, Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Idiopathic Pulmonary Fibrosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05195918's enrollment target sits among peer trials
50 33rd of 51 higher than 19 of 51 other Idiopathic Pulmonary Fibrosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Idiopathic Pulmonary Fibrosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Dose-Escalation Study of Artesunate Patients With IPF
RECRUITING · Phase 1
-
Lung and Bone Marrow Transplantation for Lung and Bone Marrow Failure
RECRUITING · Phase 1
-
A Single and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of GNS-3545 in Healthy Participants
RECRUITING · Phase 1
-
NAL ER IPF Respiratory Function and Safety Study
RECRUITING · Phase 1
-
Molecular Imaging Probes to Inform Heterogeneity in Idiopathic Pulmonary Fibrosis
RECRUITING · Phase 1
-
Atezolizumab for Idiopathic Pulmonary Fibrosis
ACTIVE NOT RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI